The observed inverse correlation between GPD1L expression and therapeutic response highlights its potential utility in predicting treatment outcomes and guiding the stratification of targeted therapies in HCC patients based on GPD1L gene expression status, particularly in FAK inhibitors. Here, GPD1L is linked to hepatocellular carcinoma.